RECRUITINGEarly Phase 1INTERVENTIONAL
To Check Comparison of Apremilast and Methotrexate Efficacy in Patients With Moderate to Severe Plaque Psoriasis Presented to Tertiary Care Hospital
Comparison of Efficacy of Methotrexate vs Apremilast in Moderate to Severe Plaque Psoriasis
About This Trial
This study aims to compare efficacy of methotrexate vs apremilast in the management of chronic plaque psoriasis.Given the high prevalence of psoriasis in Pakistan and the significant psychological impact on patients, particularly in Peshawer,this study will provide valuable insights into optimal treatment strategies.
Who May Be Eligible (Plain English)
Who May Qualify:
Patients having age between 18-60 years of either gender Diagnosed with moderate to severe plaque psoriasis (PASI ≥10) No previous cancer treatment that works throughout the body (like chemotherapy) in past 3 months.
Who Should NOT Join This Trial:
Pregnancy or lactation History of liver or renal dysfunction Known hypersensitivity to study drugs
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
Patients having age between 18-60 years of either gender Diagnosed with moderate to severe plaque psoriasis (PASI ≥10) No prior systemic therapy in past 3 months.
Exclusion Criteria:
Pregnancy or lactation History of liver or renal dysfunction Known hypersensitivity to study drugs
Treatments Being Tested
DRUG
Methotrexate
Group A will recieve methotrexate 10-25mg once weekly for 3 months. Along with folic acid once daily except on day of methotrexate.
DRUG
Apremilast
Group B will recieve tablet apremilast 30mg twice daily for 3 months.
Locations (1)
MTI-HMC Peshawar
Peshawar, Khyber Pukhtunkhwa, Pakistan